Picture of Neuronetics logo

STIM Neuronetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Neuronetics Inc expected to post a loss of 42 cents a share - Earnings Preview

* Neuronetics Inc  STIM.OQ   STIM.O  is expected to show a
rise in
quarterly revenue when it reports  results on November 8. 
    * The Malvern Pennsylvania-based  company is expected to
report  a
8.8% increase in revenue to $15.016 million from $13.8 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. The company's guidance on August 2 2022, for
the period ended September 30, was for revenue between $14.50
million and $15.50 million.
    * ​Refinitiv's mean analyst estimate for Neuronetics Inc is
for a
loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neuronetics
Inc
is $9​, above​ its last closing price of $3.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.41       -0.41      -0.39     Beat    5.3
 Mar. 31 2022  -0.40       -0.40      -0.41     Missed  -2.6
 Dec. 31 2021  -0.31       -0.32      -0.29     Beat    8.2​
 Sep. 30 2021  -0.32       -0.30      -0.31     Missed  -2.6
 ​​Jun.        -0.24       -0.24      -0.29     Missed  -20.8
 30 2021                                                
 Mar. 31 2021  -0.29       -0.31      -0.31     Met     0​
 Dec. 31 2020  -0.23       -0.24      -0.19     Beat    21.1
 Sep. 30 2020  -0.27       -0.28      -0.18     Beat    36
 This summary was machine generated November 4 at 19:35 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Neuronetics

See all news